Sarepta Therapeutics Inc (SRPT): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Sarepta Therapeutics ( SRPT) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.3%. By the end of trading, Sarepta Therapeutics fell $1.16 (-4.8%) to $23.09 on light volume. Throughout the day, 1.7 million shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 2.5 million shares. The stock ranged in price between $22.81-$24.67 after having opened the day at $24.50 as compared to the previous trading day's close of $24.25. Other companies within the Health Care sector that declined today were: Cormedix ( CRMD), down 15.7%, Spherix ( SPEX), down 14.1%, XenoPort ( XNPT), down 11.9%, and Thermogenesis Corporation ( KOOL), down 11.1%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of serious and life-threatening rare and infectious diseases. Sarepta Therapeutics has a market cap of $527.8 million and is part of the drugs industry. Shares are up 3155% year to date as of the close of trading on Wednesday. Currently there are five analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and weak operating cash flow.

On the positive front, Chelsea Therapeutics International ( CHTP), up 28%, Nymox Pharmaceutical Corporation ( NYMX), up 15.3%, Cempra ( CEMP), up 10.8%, and MEI Pharma ( MEIP), up 10.8%, were all gainers within the health care sector with Biogen Idec ( BIIB) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

With an Eye on Biotech, Here's Today's Trading Thesis

With an Eye on Biotech, Here's Today's Trading Thesis

Focused on Two Sectors

Focused on Two Sectors

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

In This Booming Stock Market, Think Like a Programmer Not a Critic

In This Booming Stock Market, Think Like a Programmer Not a Critic

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits